The MET pathway is constitutively phosphorylated/activated with loss of the VHL protein [6], a feature present in over 80% of cases of clear cell RCC (ccRCC) [7, 8]. In vitro studies have demonstrated that with VHL loss, activation of the MET pathway drives a more invasive phenotype [9]. Here, MET is linked to nonpapillary renal cell carcinoma.